

























Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Mitochondrial Biogenesis: A Potential Therapeutic Target for Osteoarthritis 




1) Grupo de Investigación en Reumatología. Instituto de Investigación Biomédica de A 
Coruña (INIBIC). Agrupación estratégica CICA-INIBIC. Complexo Hospitalario 
Universitario de A Coruña (CHUAC), Sergas. Department of Medicine, Universidade de 
A Coruña (UDC), Spain. 







Keywords: Mitochondrial dynamics, Mfn2, Osteoarthritis,  
Address correspondence to:  
 
Francisco J. Blanco 
INIBIC-Hospital Universitario A Coruña, Xubias, 84,  
15006 A Coruña,  
Spain. 




Osteoarthritis (OA), the most frequent joint disease, is a heterogeneous disorder. Genetic, 
ageing, biomechanical, metabolic and inflammatory factors are involved in its 
pathogenesis (1). Mitochondrial dysfunction of human articular chondrocytes is 
considered a hallmark of cartilage degradation and OA pathogenesis (2-5). 
Due to the huge number of cellular processes in which mitochondria is implicated, 
even in the closed context of cellular respiration, the term mitochondrial function can 
refer to a variety of features which include fusion and fission, turnover (biogenesis and 
mitophagy), and plasticity (6). The consideration of these mitochondrial capabilities has 
advanced our understanding of how the cell may respond to metabolic disturbances such 
as oxidative stress, inflammation, and gluco- and lipotoxicity (7). 
Mitochondrial fission and fusion control number, distribution, and morphology of 
these organelles in the cell and therefore play important roles for diverse mitochondrial 
functions such as energy production, metabolism, intracellular signaling and apoptosis (8, 
9). Fission is needed to created new mitochondria and it is mediated by dynamic-related 
peptide 1 (Drp1) and fission protein 1 (Fis1) (8). Mitochondrial fusion is controlled by 
GTPase enzymes; namely mitofusins 1 and 2 (Mfn1 and Mfn2), that control outer 
mitochondrial membrane fusion, and optic atrophy 1 (Opa1) that governs inner 
mitochondrial membrane fusion (9). Fusion has several essential roles inside the cells, for 
example, it helps mitigate cellular stress by removing damaged mitochondria through 
mitophagy (23).  
 The balance between fission and fusion is a key mechanism in the regulation of 
mitochondrial structure, function and cellular health (8, 11). Mitochondrial dynamics are 
altered in several illnesses such as insulinǦresistance (12), type 2 diabetes (13), several 
neurodegenerative diseases (14) including $O]KHLPHU¶V GLVHDVH (15), cancer (16), 
cardiovascular alterations (17, 18) and ischemic and dilated cardiomyopathy (19, 20).  
Given the relevance of mitochondrial morphology in the regulation of multiple cell 
functions, and its potential connection with several pathologies, the importance of a 
detailed knowledge of the molecules/mechanisms that govern mitochondrial fusion and 
fission processes seems clear.  
In the current issue of Osteoarthritis and Cartilage, Xu and co-workers investigate 
the effect of mitochondrial fusion on metabolic changes during aging and OA. They 
define the impact of Mfn2 on OA progression both in vitro and in vivo models. Authors 
tested the expression of OPA1, MFN1 and MFN2, the most relevant proteins involved in 
mitochondrial fusion, and results showed a significant increase in Mfn2 expression during 
aging, as well as OA, suggesting that MFN2 contributed to mitochondrial dynamics 
impairment in chondrocytes during aging. To ascertain whether MFN2 regulated 
metabolic changes of aging cells, they knocked down Mfn2 with small interfering RNA 
and found that basal and maximal oxygen consumption rates (OCR) were downregulated 
while glucose uptake was upregulated, suggesting a metabolic shift from oxidative 
phosphorylation to glycolysis.  
 
These results disagree with other authors reporting that Mfn2 knockdown 
suppresses mitophagy in different cell types, such as cardiomyocytes or neurons, resulting 
in the accumulation of damaged mitochondria and pathological conditions (21). 
Similarly, age-related Mfn2 depletion in muscles was identified as a link between an 
inhibition of mitophagy, and the subsequent accumulation of dysfunctional mitochondria, 
to sarcopenia (21). Mfn2 expression has also been found to be reduced in obesity and type 
I diabetes, two diseases associated with OA. MFN2 down-regulation activates the JNK 
pathway, favoring the formation of lipid intermediates that lead to insulin resistance in 
both skeletal muscle and liver (22). 
 
 
MFN1 and MFN2 are homologous proteins that belong to the large family of 
mitochondrial trans-membrane GTPases and share some functions in the mitochondrial 
fusion process. Mfn1 plays a more relevant role in mitochondrial fusion, whereas MFN2 
mainly affects mitochondrial metabolism by regulating several mitochondrial functions 
such as membrane potential, fuel oxidation and the OXPHOS system (23). A fused, 
continuous network is associated to a higher ATP production, likely due to optimized 
exchanges of metabolites within their matrix. However, Xu et al. found declined, rather 
than elevated, ATP production by Mfn2 knockdown.  
We agree with the authors' proposal to explain this discrepancy, as well as the 
differences found compared to cardiomyocytes and neurons and the data reported in 
diabetes mellitus and obesity. They argue that these previous results were obtained in 
models with a metabolism predominantly based on oxidative phosphorylation, while the 
metabolism of the chondrocyte in situ is mainly glycolytic. As a result, any action that 
promotes an increase in the oxidoreductive metabolism, such as mitochondrial fusion, 
would generate higher levels of ATP, ROS and inflammation mediators, causing damage 
to the chondrocyte and to cartilage.  
 
This hypothesis is supported by their experiments using lentiviruses to establish 
Mfn2 overexpression/knockdown models. Results strongly suggested that Mfn2 
overexpression played a pro-inflammatory role in DMM models by upregulating the 
expression of inflammation-related genes, including COX2 and MMP13, via NF-ț%
pathway, and that knockdown of Mfn2 had a protective effect against OA progression. In 
contrast, Chen Y et al. reported that Mfn2 expression was decreased in human nucleus 
pulposus tissues during intervertebral disc degeneration. In addition, these authors 
showed that Mfn2 knockdown aggravated the impairment of autophagic flux, 
mitochondrial dysfunction and cellular apoptosis in rat nucleus pulposus cells, while 
Mfn2 overexpression significantly reversed these alterations (24).  
Thus, both increased and decreased Mfn2 expression have been found in different 
disease experimental models (human and animal). All these data support the idea that 
MFN2 expression differs between organs and tissues, much like bioenergetic efficiencies 
and mechanisms of adaptation to nutrient availability.  
Mitochondria biogenesis (fission, fusion and mitophagy) represent an attractive 
therapeutic target to treat multiple diseases such as Alzheimer (15), age-related skeletal 
muscle alteration (255) or several cancers (26). Pharmacological inhibition of fission may 
only be protective in the short-term, because chronic inhibition would be detrimental to 
the organs as fission is critical to maintaining a healthy mitochondrial network (27, 28). 
In the case of OA, according to the results reported, the therapeutic target must be focused 
on reducing mitochondrial fusion and Mfn2 expression. In this sense, increasing the levels 
of ubiquitin E3 ligase Parkin (PARKIN) could be a good option. The process for culling 
damaged mitochondria is mediated via PTEN-induced putative kinase 1 (PINK1) which 
is stabilized on the mitochondria membrane and recruits the PARKIN that, in turn can 
ubiquitinate MFN2. The poly-ubiquitination of MFN2 leads to the engulfment of 
mitochondria in the autophagosome via P62/Beclin 1, LC3 activation and fusion with 
lysosomes (29, 31. Data reported so far support this hypothesis, loss of PARKIN function 
contributes directly to the pathogenesis of OA (32) and the elevated expression of MFN2 
in OA cartilage is a result of the declined levels of PARKIN. 
In summary, mitochondrial biogenesis and mainly mitochondrial fusion and reduced 
mitophagy, contribute to the metabolic disorder and inflammation that occurs during OA. 
Reduced MFN2 and increased PARKIN expression represent potential therapeutic targets 
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Figure. MFN2 is involved in the mitochondrial dynamics, an essential process to 
eliminate damaged mitochondria in response of damage accumulation. This process is 
mediated via PINK1, who recruits Parkin, which can poly-ubiquitinate MFN2 leading the 
mitophagy process. However, MFN2 can block the mitophagy, damaged mitochondria 
are accumulated inside the cells causing an increase of apoptosis, oxidative stress, 
mitochondrial dysfunction, mitochondrial fragmentation. All these processes are related 
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